In Vitro Antitumor Effects of AHR Ligands Amino Flavone (AFP 464) and Benzothiazole (5F 203) in Human Renal Carcinoma Cells

Gabriela A. Luzzani,1 Mariana A. Callero1,2, Anchala I. Kuruppu,3 Valentina Trapani,4 Carolina Flumian,1 Laura Todaro,1,2 Tracey D. Bradshaw,3 and Andrea I. Loaiza Perez1,2*

1Universidad de Buenos Aires, Instituto de Oncologia “Ángel H. Roffo”, Área Investigaciones, Ciudad de Buenos Aires, Argentina
2National Scientific Council (CONICET), Ciudad de Buenos Aires, Argentina
3School of Pharmacy, University of Nottingham, Nottingham, UK
4Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, Roma, Italia

ABSTRACT

We investigated activity and mechanism of action of two AhR ligand antitumor agents, AFP 464 and 5F 203 on human renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis, and migration. TK-10, SN12C, Caki-1, and ACHN human renal cancer cell lines were treated with AFP 464 and 5F 203. We evaluated cytotoxicity by MTS assays, cell cycle arrest, and apoptosis by flow cytometry and corroborated a mechanism of action involving AhR signal transduction activation. Changes in migration properties by wound healing assays were investigated: 5F 203-sensitive cells show decreased migration after treatment, therefore, we measured c-Met phosphorylation by Western blot in these cells. A 5F 203 induced a decrease in cell viability which was more marked than AFP 464. This cytotoxicity was reduced after treatment with the AhR inhibitor α-NF for both compounds indicating AhR signaling activation plays a role in the mechanism of action. A 5F 203 is sequestered by TK-10 cells and induces CYP1A1 expression; 5F 203 potently inhibited migration of TK-10, Caki-1, and SN12C cells, and inhibited c-Met receptor phosphorylation in TK-10 cells. AhR ligand antitumor agents AFP 464 and 5F 203 represent potential new candidates for the treatment of renal cancer. A 5F 203 only inhibited migration of sensitive cells and c-Met receptor phosphorylation in TK-10 cells. c-Met receptor signal transduction is important in migration and metastasis. Therefore, we consider that 5F 203 offers potential for the treatment of metastatic renal carcinoma. J. Cell. Biochem. 118: 4526–4535, 2017. © 2017 Wiley Periodicals, Inc.

KEY WORDS: AFP 464; 5F 203; AhR; HUMAN RENAL CANCER

The aryl hydrocarbon receptor (AhR) is a cytosolic transcription factor. After binding with its ligand, the receptor translocates to the nucleus, binds to xenobiotic response element (XRE) promoter sequences, activating target genes including cytochrome P4501A1 (CYP1A1). Initially, AhR was linked to detoxification functions of cell products and environmental pollutants. Our research group has described a new role for the AhR signaling pathway as a novel molecular target for cancer therapeutics. Currently, there are two antitumor agent AhR ligands, that have been tested clinically (Fig. 1): amino flavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. It has been proven that 5F 203 and AFP 464 are AhR-targeted agents [Loaiza-Pérez et al., 2002, 2004]. The benzothiazole 5F 203 lysylamide prodrug Phortress, tested in phase I clinical trials, achieved disease stabilization in 28% patients recruited [Seckl et al., 2012], although neither breast nor ovarian carcinoma patients received Phortress. Preclinically, 5F 203, and Phortress evoked potent antiproliferative activity in breast and ovarian tumor models, inducing...
CYP1A1 expression and generating DNA adducts which are converted to lethal strand breaks in sensitive cell lines and xenografts only [Bradshaw et al., 2002; Leong et al., 2004]. We have previously described that 5F 203 induced enhanced AhR nuclear translocation and CYP1A1 expression in human breast cancer cells [Trapani et al., 2003], in the human ovarian cell line IGROV-1. In ascites-isolated ovarian cancer cells, sensitivity to 5F 203 correlated with cytosolic AhR translocation to nuclei, upon treatment of ovarian cancer cells ex vivo. 5F 203 possessed antiproliferative/pro-apoptotic activity inducing oxidative stress measured as ROS formation, JNK, ERK, and P38MAPK phosphorylation, DNA damage and cell cycle arrest prior to apoptosis. In contrast, 5F 203 failed to induce CYP1A1 expression, AhR translocation, or oxidative stress in 5F 203-resistant SKOV-3 cells [Callero et al., 2013].

Interestingly, preclinical NCI 60 cell line panel data showed that TK-10 cells and other human renal cancer cell lines were consistently sensitive to 5F 203 and Phortress [Kashiyama et al., 1999]. Intriguingly, Phortress stabilized disease in the two renal carcinoma patients recruited to trial (in 1 patient, stability was maintained for 16 cycles). Therefore, in this study we sought to examine AhR pathway activation and CYP1A1 inducibility in TK-10 and other renal carcinoma cell lines after treatment with 5F 203. Given the poor prognosis associated with kidney cancer and the paucity of therapeutic options, preclinical investigations of the use of amino-phenylbenzothiazole experimental antitumour agents against these tumors are warranted.

Amino-avone (AF; NSC 686288, AFP 464, NSC710464) is a new anticancer agent undergoing phase II clinical evaluation. It has demonstrated antiproliferative effects in MCF-7 human breast cancer cells mediated by AhR. AF also exhibits noteworthy evidence of antitumor activity in vitro and in vivo against neoplastic cells of renal origin. AF treatment of sensitive renal cells, in contrast to resistant cells, promoted the induction of CYP1A1, the covalent binding of AF-reactive intermediates, and apoptosis [Loaiza-Perez et al., 2004]. AF treatment also induced apoptosis, in human renal cancer sensitive cells for example, TK-10, Caki-1 and SN12C, which was not observed in ACHN resistant cells. AF induced time-dependent AhR nuclear translocation and AhR transcriptional activity in sensitive renal cancer cell lines. A renal cell strain derived from a human papillary tumor also showed sensitivity to AF, as well as AhR pathway activation and drug-induced apoptosis. AhR translocation was proposed as a marker of sensitivity to AF in sensitive renal tumor cells of different histological origin, for clinical trials [Callero et al., 2012]. Emphasis has been placed on the vascular endothelial growth factor (VEGFR), platelet derived growth factor, and PI3K pathways, leading to the development, and Food and Drug Administration (FDA)-approval of multiple targeted agents for RCC [Linehan et al., 2007]. As these drugs generally slow the progression of disease with only modest objective responses, it is necessary to identify new molecular targets in RCC for the development of more effective therapeutic strategies. Dysregulation of c-Met and its ligand, hepatocyte growth factor (HGF), have been implicated in tumor development, invasion, and angiogenesis in malignancies. Mutations in the c-Met gene have been identified in papillary RCC [Gibney et al., 2013]. It has been shown that loss of von Hippel-Lindau (VHL) expression and hypoxia lead to upregulation of c-Met expression in clear cell RCC. Studies performed in clear cell lines demonstrated that c-Met protein was activated in renal cancer cell lines, and cell proliferation was blocked by SU11274 (sunitinib) and ARQ 197 [Gibney et al., 2013].

Kidney cancer rapidly acquires resistance to antiangiogenic agents such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Met signal transduction). The aim of this study was to investigate the action of AFP 464, the amino-flavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells specifically examining their effects on cell cycle progression, apoptosis, and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited migration of TK-10, Caki-1, and SN12C cells and the migration signal transduction cascade, involving c-Met signaling in TK-10 cells.

MATERIALS AND METHODS

CELL LINES

The following human renal cancer cell lines were obtained from the National Cancer Institute (NCI) repository: TK-10, SN12C, Caki-1, and ACHN. They were cultured in 25 cm² flasks with 5% CO₂ in RPMI medium (Gibco) supplemented with 10% fetal bovine serum (FBS; PAA).

ANTIPROLIFERATIVE ACTIVITY

Renal cell lines grown in 25 cm² flasks were removed by trypsinization and seeded into 96-well culture dishes at a concentration of 750 cells per well. Cells were allowed to grow for 48 h at 37°C in a humidified atmosphere containing 5% CO₂.
AFP 464 treatment: Cells were treated with AFP 464: 10, 100, 500 nM and 1 μM or dextrose water (control) for an additional 120 h.

5F 203 treatment: Cells were treated with 5F 203: 100 nM, 500 nM, 1, 10, and 100 μM or DMSO (0.1%) (control) for an additional 120 h.

In both cases cell viability was determined by the MTS method (Promega). To study AhR pathway involvement, cells were pre-incubated for 1 h with AhR specific antagonist a-NF (1 mM).

CELL CYCLE PROGRESSION
Cells were seeded into 6-well culture dishes at a concentration of 3 × 10^5 cells per well. After 24–48 h, cells were treated with these agents:

- **AFP 464**: Control (dextrose water); α-NF (1 μM); AFP 464 (1 μM) for 24 and 48 h; pre-incubation for 1 h with α-NF (1 μM) followed by α-NF (1 μM) + AFP 464 (1 μM) for 24 and 48 h.
- **5F 203**: Control (DMSO 0.1%); α-NF (1 μM); 5F 203 (1 μM) for 24 and 48 h; pre-incubation for 1 h with α-NF (1 μM) followed by α-NF (1 μM) + 5F 203 (1 μM) for 24 and 48 h.

Thereafter, cells were harvested, washed in PBS, and fixed in 70% ethanol. DNA was stained by incubating cells in PBS containing propidium iodide; fluorescence was measured and analyzed using Cylogic software version 1.2.1. DNA analyzes allowed us to determine the cell distribution in each cell cycle phase.

DETECTION OF 5F 203 IN NUTRIENT MEDIUM
TK-10 cells were seeded into 25 mL flasks and allowed 24 h to adhere and begin mitoses. Medium was changed and 5F 203 introduced at a final concentration of 100 nM. Media, collected from flasks at time zero, 4, 24, 48, and 72 h thereafter, were mixed with threefold volumes of HPLC-grade acetonitrile. Protein was precipitated by centrifugation at 14,000 rpm for 10 min, and supernatants analyzed by HPLC. The analytical system consisted of a Hewlett-Packard1050 series module (solvent delivery pump, autosampler, and multiple wavelength detector) and a Hewlett-Packard 1046A fluorescence detector. 5F 203 separation was effected at room temperature on a C18 reversed-phase column (150/x 4.6 mm i.d.) using a mobile phase of 65% methanol and 35% H2O, delivered at a flow rate of 1 mL/min. 5F 203 eluted at 338 nm; was identified with UV detection and with fluorescence detection (excitation 344 nm; emission 434 nm) and confirmed by chromatographic analysis of authentic 5F 203.

WOUND HEALING
To analyze the effect of AFP 464 or 5F 203 on migration, cells were seeded in 6-well plates and incubated for 48 h so as to achieve an 80–90% confluent monolayer. Cells were treated for 24 h with 10^{-4}–1 μM AFP 464 or 5F 203. After this time had elapsed, a single scratch wound was created in the monolayer with a tip and then immediately photographed at time 0 and T_f (approximately 18 h later, depending on each cell line). Cell migration was assessed by determining the covered area at T_0 and T_f with the program Image J and then the percentage migration was calculated using the following equation: (T_f - T_0)/T_0. We considered 20 fields per plate. Migration percentage was analyzed with the program GraphPad Prism5.

**Fig. 2.** AFP and 5F 203 effect on cellular viability. Cells were incubated with AFP 464 or dextrose water for 5 days (A) or cells were incubated with AFP 464 (1 mM) for 5 days alone or pre-treated for 1 h with α-NF (1 mM) and then treated with AFP 464 (1 mM) plus α-NF (1 mM) for 5 days (B). Cellular viability was assessed by MTS assay. The values represent the average of three independent experiments, *P < 0.05 with respect to control cells. Cells were incubated with 5F 203 or DMSO (0.1%) for 5 days (C) or cells were incubated with 5F 203 (1 mM) for 5 days alone or pre-treated for 1 h with α-NF (1 mM) and then treated with 5F 203 (1 mM) plus α-NF (1 mM) for 5 days (D). Cellular viability was assessed by MTS assay. The values represent the average of three independent experiments, *P < 0.05 with respect to control cells.
Wounds were photographed, imaged under a phase contrast microscope.

**WESTERN BLOT**

Cells were seeded in dishes (100 x 20 mm) at a density of 1 - 2 x 10^6 per dish, allowed 24 h to attach, before being exposed to 5F 203 (1 M, 5, 10, 30 min, 1, 4, or 24 h). Following exposure, cell lysates were prepared and protein concentrations evaluated by Bradford assay [Bradford, 1976]. Proteins (50 µg per simple) were separated by PAGE. CYP1A1, c-Met, phosphorylated c-Met, and GAPDH 1° Abs were purchased from Cell Signaling Technologies. A 2° Abs were obtained from Dako. Densitometric analyses of Western blots were performed using Image J.

Fig. 3. AFP 464 altered cell cycle distribution. The effect of 1 µM AFP 464 on cell cycle distribution: Cells were harvested, washed with PBS, and fixed in 70% ethanol, then stained with propidium iodide and analyzed by flow cytometry. (A) The values represent the average of three independent experiments, *P < 0.05; **P < 0.01 with respect to control cells. (B) Cell cycle frequency histograms correspond to one representative experiment of three is shown; 20,000 events were analyzed.
RESULTS

**AFP 464 AND 5F 203 INDUCE CYTOTOXICITY IN HUMAN RENAL CANCER CELL LINES**

In this study, we measured the sensitivity of cells to AFP 464 as an in vitro regression (shown by a decrease in cell metabolism measured by the MTS assay).

The incubation of TK-10, SN12C, and Caki-1 cells with 1 μM AFP 464 for 5 days induced a significant decrease in cell viability (compared to control viability, considered to be 100%; TK-10, 21.22 ± 10.9%; SN12C, 50.91 ± 4.9%; Caki-1, 87.24 ± 9.1% cells; Fig. 2A). Effects were dependent on drug concentration. In contrast, ACHN cells were not sensitive to AFP 464 as significant growth inhibition was not observed at any drug concentration (Fig. 2A). In
order to investigate whether the sensitivity of renal cancer cells to AFP 464 is mediated by AhR activation, we pre-incubated the cells with the AhR specific inhibitor, α-NF (1 μM), for 1 h prior to treatment with 1 μM AFP 464 plus α-NF. The AhR inhibitor significantly reduced the cytotoxic effects of AFP 464 in TK-10 and partially reduced the cytotoxic effects in SN12C with respect to control (Fig. 2B).

In addition, sensitivity of TK-10, SN12C, and Caki-1 cells to 5F 203 was also measured. Interestingly, incubation of these cell lines with 0.1 μM 5F 203 for 5 days dose-dependently decreased cell viability, more remarkably than did AFP 464 (survival was calculated as TK-10: 45 ± 10%; SN12C, 26 ± 3%; Caki-1, 36 ± 3%, with respect to the control which was considered 100%; Fig. 2C). As with AFP 464, the cell line ACHN did not show sensitivity to 5F 203. Involvement of the AhR pathway was assessed by using the AhR specific inhibitor (α-NF; 1 μM); results show that the cytotoxic effects of 5F 203 were significantly diminished in TK-10 and SN12C cells by α-NF-mediated inhibition of AhR signal transduction (Fig. 2D).

**AFP 464 AND 5F 203 ALTERED CELL CYCLE DISTRIBUTION AND EVOVED APOPTOSIS IN SENSITIVE RENAL CANCER CELLS**

As previous results indicate that AFP 464 (NSC710404) induced DNA damage and apoptosis in renal cancer cells [Callero et al., 2012] and 5F 203 evoked DNA damage in breast and ovarian cancer cells, we investigated perturbations in the cell cycle after treatment of renal cells with AFP 464 and 5F 203. For this approach, cells were exposed to 1 μM AFP 464, 1 μM 5F 203, or 0.1% DMSO for 24 and 48 h and subsequently processed for cell cycle analyses. As illustrated (Fig. 3), AFP 464 only caused an increase in phase G0/G1 in TK-10 cells at 24 h (56.7 ± 0.15% control; 61.65 ± 1.65% at 24 h). However, significant accumulation of sub-G0 events was detected in TK-10 cells from 2.5 ± 0.6% (control) to 8.13 ± 0.2% at 48 h, in SN12C cells 6.2 ± 0.7% (control) to 17.64 ± 0.9% at 48 h, and Caki-1 from 2.44 ± 0.2% (control) to 6.05 ± 1% at 48 h. In contrast, ACHN cell cycle was not perturbed following treatment with AFP 464.

5F 203 caused an increase in phase G0/G1 in SN12C and Caki-1 cells. While this effect was observed at 24 h in SN12C cells (control: 54.8 ± 0.62% vs. 24 h: 73.48 ± 5.44%), in Caki-1 cells G0/G1 arrest was seen at 24 and 48 h (control: 52.05 ± 0.47%, 24 h: 61.9 ± 3.9%, 48 h: 64.34 ± 2.03%). Accumulation of Sub-G0 events was observed in TK-10, SN12C, and Caki-1 cells at both assayed times. TK-10 cells: from 4.15 ± 2.13 (control) to 6.4 ± 2.4% and 11.0 ± 0.4 (24 and 48 h, respectively); SN12C cells: from 0.76 ± 0.64% to 4.6 ± 1.4%, and 11.1 ± 0.4% (24 and 48 h, respectively); Caki-1 cells: from 2.4 ± 0.22% to 4.2 ± 1.09% and 4.6 ± 1.6% (24 and 48 h, respectively). In contrast, ACHN cell cycle was not perturbed following treatment with 1 μM 5F 203 (Fig. 4).

5F 203 IS DEPLETED FROM MEDIUM OF TK-10 CELLS AND INDUCES EXPRESSION OF CYP1A1

It has previously been reported that 5F 203 is stable in medium [Hutchinson et al., 2001]. When added to TK-10 cancer cell nutrient medium (100 nM 5F 203), 5F 203 was rapidly depleted (Fig. 5A). After 24 h ~60% depletion was noted after treatment of cells with 100 nM 5F 203; after 72 h treatment, medium levels of 5F 203 were below detection levels.

Potent cytosolic AhR ligands, aminophenylbenzothiazoles (including 5F 203) have also been reported to activate AhR signaling, there by inducing expression of CYP1A1 [Chua et al., 2000; Hutchinson et al., 2001; Loaiza-Perez et al., 2002] In lysates of TK-10 cells exposed to fluorinated 2-(4-amino-3-methylphenyl) benzothiazole analogs including 5F 203 (1 μM; 24 h) CYP1A1 protein could be detected (Fig. 5B).

**IMPACT OF AFP 464 AND 5F 203 TREATMENT ON CELL MIGRATION**

We investigated the effect of AFP 464 and 5F 203 treatments on migration of renal tumor cells in vitro. As shown in Figure 6, AFP 464 treatment decreased migration neither in the sensitive nor in the resistant cell lines (61 ± 8%, 62 ± 1%, and 64 ± 7% of migration percentage for TK-10, SN12C, and ACHN, respectively as compared to 70 ± 5%, 0.67 ± 15% and 73 ± 8% in the controls).
In contrast, 5F 203 (1 μM) significantly suppressed cell migration in the three sensitive cell lines, 42 ± 6%, 18 ± 7%, and 29 ± 2% in TK-10, SN12C, and Caki-1 cell lines, respectively as compared to 69 ± 1%, 63 ± 3%, and 62 ± 4% for controls. For the non-sensitive cell line (ACHN), migration percentage was of 46 ± 2%, as compared to 38 ± 1% for control. While in TK-10 and Caki-1 cells, treatment with 10 and 1 μM 5F 203 decreased migration, inhibition of SN12C cells migration was apparent at all concentrations examined (≥10−4 μM).

EFFECT OF 5F 203 ON C-MET PHOSPHORYLATION IN TK-10 CELLS
As treatment with 5F 203 demonstrated inhibition of TK-10 cells migration, and p-Met are involved in the migration process, cell lysates were subjected to p-Met Western blot analyses. TK-10 cells were exposed to 1 μM 5F 203 for 5, 10, and 30 min, 1, 4, or 24 h. Compared to control, c-Met phosphorylation was down-regulated at all time points examined. Particularly significant down-regulation of phospho C-Met was detected in lysates of TK-10 cells exposed to 1 μM 5F 203 for 1 h (P < 0.001; Fig. 7).

Fig. 6. AFP 464 and 5F 203 effects on cellular migration. (A) AFP 464 wound healing assay: TK10, SN12C, and ACHN cells were incubated with AFP 464 for 24 h with the dilutions described in the methodology. A wound was made with a yellow tip; the initial and final wound areas were measured (Tf = 20 h post wound) and analyzed with the Image J program. The graph shows the percentage migration for each dilution realized. Values that are significantly different from controls are indicated *P < 0.05. Representative fields from one experiment are shown under each graph. Experiments were performed in triplicate. (B) 5F 203 wound healing assay: TK10, SN12C, Caki-1, and ACHN cells were incubated with 5F 203 for 24 h with the dilutions described in the methodology. A wound was made with a yellow tip; the initial and final wound areas were measured (Tf = 14 h post wound) and analyzed with the Image J program. The graph shows the percentage migration for each dilution realized. Values that are significantly different from controls are indicated *P < 0.05. Representative fields from one experiment are shown under each graph. Experiments were performed in triplicate.
DISCUSSION

Our previous studies showed that renal cancer cell lines of human origin, such as Caki-1, TK-10 and A498, and human renal cell strains derived from patients with renal tumors were very sensitive to AF (NSC686288) [Loaiza-Pérez et al., 2004]. However, other cell lines and cell strains were classified as resistant. Treatment with AF of sensitive cells resulted in AhR signaling pathway activation which leads to CYP1A1 induction, inducing AF metabolism to reactive intermediates that cause DNA damage and apoptosis, measured by cytokeratin 18 cleavage. In our previous report, we indicated that papillary renal tumors were more sensitive to AF than clear cell tumors [Loaiza-Pérez et al., 2004]. The enhanced activity of AF against the papillary variant of renal cell carcinoma is of special value. Except for Temsirolimus and Sunitinib, there are little or no data regarding the safety and efficacy of new targeted drugs in papillary renal tumors and there is a need for the development of new effective therapies [Dutcher et al., 2009].

We suggested that the AhR may represent a new molecular target for the treatment of these tumors, distinct from proteins currently targeted in the clinic. AhR translocation and activation may be used as a biomarker in tumor biopsies to predict sensitivity to treatment with AF of renal tumors of different histological types. This could be incorporated into phase II clinical trials, together with other markers of sensitivity, such as the induction of CYP1A1, high covalent binding of metabolites, and apoptosis, for the selection of patients that potentially could respond to the treatment with this agent [Loaiza-Pérez et al., 2004; Callero et al., 2012].

Our studies showed that in sensitive cells AF induced formation of apoptotic bodies; incubation with the AhR inhibitor, α-NF, prior to treatment with AF, decreased the number of apoptotic bodies formed [Callero et al., 2012]. Indicating that AF-induced apoptosis is mediated by AhR activation. Also, we previously studied the molecular pathway involved in AF-induced apoptosis, and we observed the induction of p-P53 and P21 levels after treatment with 1 μM AF in these cells between 3 and 6 h, which confirms that this compound caused apoptosis and presumably cell cycle arrest [Callero et al., 2012]. This finding is consistent with the induction of p-P53 and P21 that was previously reported after AF treatment of MCF-7 breast cancer cells [Meng et al., 2007]. In addition, caspase 3 activation and consequent PARP cleavage after treatment with AF in TK-10 cells was found which is consistent with the DNA damage and apoptosis caused by this antitumor agent. Furthermore, caspase 3-dependent apoptotic body formation was observed in MCF-7 breast cancer cells after treatment [McLean et al., 2008], which is consistent with our observation in renal cancer cells. Since AFP 464 is a prodrug administered to patients which is metabolized to form AF, we assumed that apoptosis via p-P53 and P21 and caspase activation also occurred in our system.

In this paper we demonstrated accumulation of TK-10, SN12C, and Caki-1 events in Sub-G0 after treatment of cells with AFP 464 which indicates apoptosis caused by this clinically used amino-flavone derivative.

Our current data confirm that AFP 464 caused cytotoxicity in sensitive human renal cancer cells which was significantly reduced, when we pretreated cells with the AhR inhibitor α-NF, indicating AhR activation (Fig. 2). We confirmed that in sensitive renal cells AFP 464 induces translocation of AhR to the nucleus, indicating AhR signaling activation; in addition, histone H2AX phosphorylation indicated DNA damage caused by the drug (data not shown) [Luzzani et al., 2012].

![Fig. 7. 5F 203 effect on c-Met phosphorylation. (A) Western blots illustrating total and phosphorylated c-Met expression in lysates of TK-10 cells treated with 1 μM 5F 203 for 5, 10, 30 min, 1, 4, or 24 h. Total c-Met 10 Ab recognizes c-Met (145 KDa) and phospho c-Met 145 KDa. Representative phospho c-Met (pMet) blots are shown (n = 3). Lysates were prepared on three separate occasions; representative total c-Met (Met) and GAPDH (loading control) blots are shown. Densitometry was performed on all blots to quantify c-Met, phosphorylated c-Met, and GAPDH expression. The pMet/Met (B), pMet/GAPDH (C), and Met/GAPDH (D) ratios were calculated. The values represent the average of three independent experiments. "P < 0.05 and ""P < 0.01 with respect to control cells.](image-url)
CONCLUSIONS

AhR ligand antitumor agents, such as AFP 464 and 5F 203, represent potential new candidates for the treatment of renal cancer. Both compounds caused cell cycle arrest and apoptosis. A 5F 203 is sequestered by TK-10 cells and induces CYP1A1 expression; 5F 203 potently inhibited migration of TK-10, Caki-1, and SN12C cells, and inhibited c-Met receptor phosphorylation in TK-10 cells. C-Met receptor signal transduction promotes migration and metastasis. Therefore, we consider that 5F 203 offers potential for the treatment of metastatic renal carcinoma.

REFERENCES

Bazzi R, Bradshaw TD, Rowlands JC, Stevens MFG, Bell DR. 2009. 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor. Toxicol Appl Pharmacol 237(1):102–110.

Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.

Bradshaw TD, Bibhy MC, Double JA, Fichtner I, Cooper PA, Alley MC, Donohue S, Stinson SF, Tomaszewski JE, Sausville EA, Stevens MF. 2002. Preclinical evaluation of amino acid produgs of novel antitumor 2-[4-amino-3-methylpheny]benzothiazoles. Mol Cancer Ther 1(4):239–246. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=Preclinical%20+Evaluation%20+of%20+Amino%20+Acid%20+Prodrugs%20+of%20+Novel%20+Antitumor%20+2-[4-Amino-3-Methylphenyl]Benzothiazoles.

Bradshaw T, Stevens M, Plummer E, Calvert H. 2009. Preliminary clinical experiences of Phortress: Putative role for c-MET inhibition in antitumor activity. Mol Cancer Ther 8(12):B59.

Callero MA, Suárez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AL. 2012. Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment.—PubMed—NCBI. Int J Oncol 41(1):125–134.

Callero MA, Luzzani GA, De Dios DO, Bradshaw TD, Loaiza-Perez AL. 2013. Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) in ovarian cancer. J Cell Biochem 114(10):2392–2404.

Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF. 2000. Role of CyP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60(18):5196–5203.

Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G. 2009. Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202–209.

Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. 2013. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24(2):343–349.

Hutchinson I, Chua MS, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MF. 2001. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44(9):1446–1455.

Ishida M, Mikami S, Shinjojima T, Kosaka T, Mizuno R, Kikuchi E, Miyajima A, Okada Y, Oya M. 2015. Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke. Int J Cancer 137(2):299–310.

Kashiyama E, Hutchinson I, Chua MS, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, Stevens MFG. 1999. Antitumor benzothiazoles. 8.1 Synthesis, metabolic formation, and biological properties...
of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)-benzothiazoles. J Med Chem 42(20):4172–4184.

Leong C, Suggitt M, Swaine D, Bibby M, Stevens M, Bradshaw T. 2004. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Therap 3(12):1565–1575.

Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L. 2007. Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13(2 Pt 2):671s–679s.

Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. 2004. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Therap 3(6):715–725.

Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Lineham WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT. 2004. Sensitivity of renal cell carcinoma to Aminoflavone: Role of CYP1A1. J Urol 171(4):1688–1697.

Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MFG, Bradshaw TD, Sausville EA. 2002. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 61(1):13–19.

Luzzani G, Callero MA, Loaiza Perez A. 2012. Hormones in urologic health and development. “Aryl hydrocarbon receptor activation by aminoflavone (AFP464): New molecular target for renal cancer treatment,” in Association Summer Research Conference. Linthicum, Maryland, USA.

McLean L, Soto U, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E. 2008. Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int J Cancer, J Int du Cancer 122(7):1665–1666. NIH Public Access.

Meng L-H, W Kohn K, Pommier Y. 2007. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686, 288). Oncogene 26(33):4806–4816.

Seckl M, Cresti N, Boddy A, Phillips R, Chapman F, Schmid P, Calvert H, Robson L, Plummer R. 2012. A Cancer Research UK Phase I Trial of Phortress (Novel Antitumour Benzothiazole) Given Intravenously in Consecutive 21 Day Cycles with Treatment on Day 1 of Each Cycle, in 8th NCRI Cancer conference, Liverpool UK.

Trapani V, Patel V, Leong C-O, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MFG, Sausville EA, Loaiza-Perez AI. 2003. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 88(4):599–605.